Sector Expert: Mark Breidenbach

H.C. Wainwright & Co.



Recent Quotes

— Mark Breidenbach, H.C. Wainwright & Co. (3/31/16)
more >

"CANF's Phase 3 CF101 trial in RA could begin enrollment in Q2/16."

— Mark Breidenbach, H.C. Wainwright & Co. (1/7/16)
more >

"CANF is slated to initiate two pivotal studies in 2016."

— Mark Breidenbach, H.C. Wainwright & Co. (11/30/15)
more >

"Data show CANF's CF102 has activity in an animal model of NASH."

— Mark Breidenbach, H.C. Wainwright & Co. (11/24/15)
more >

"RXII is an underappreciated innovator with long-term upside."

— Mark Breidenbach, H.C. Wainwright & Co. (11/13/15)
more >

"RXII is an underappreciated innovator with upside long term."

— Mark Breidenbach, H.C. Wainwright & Co. (10/19/15)
more >

"RXII now may proceed with IRB submission for its Phase 1/2 AMD study."

— Mark Breidenbach, H.C. Wainwright & Co. (9/1/15)
more >

"CANF is finalizing protocols for the next trials of CF101 in RA."

— Mark Breidenbach, H.C. Wainwright & Co. (8/31/15)
more >



Due to permission requirements, not all quotes are shown.